| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors (NCT05124743) | Alaunos Therapeutics | 2021-09-24 |
| A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer (NCT05053230) | Memorial Sloan Kettering Cancer Center | 2021-09-20 |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients (NCT05044091) | Xiaoxiang Chen | 2021-09-15 |
| A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice (NCT05021562) | Takeda | 2021-09-13 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction (NCT06065358) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-09-13 |
| A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer (NCT04787289) | British Columbia Cancer Agency | 2021-09-10 |
| CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (NCT03944902) | University of Alabama at Birmingham | 2021-09-01 |
| A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy (NCT04814875) | THERAPIM PTY LTD | 2021-09-01 |
| Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer (NCT05446545) | Fudan University | 2021-09-01 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study (NCT05223218) | Namida Lab | 2021-08-25 |
| Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (NCT04881045) | Pfizer | 2021-08-18 |
| Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation (NCT06518746) | University of Colorado, Denver | 2021-08-16 |
| Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217) | ImmVira Pharma Co. Ltd | 2021-08-10 |
| Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (NCT05051722) | Mayo Clinic | 2021-08-03 |
| DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (NCT03905902) | SOTIO a.s. | 2021-08-01 |
| Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients (NCT05273944) | Shenzhen Kangzhe Pharmaceutical Co., Ltd. | 2021-07-28 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Connecting Families to Overcome Ovarian Cancer (NCT04927013) | Emory University | 2021-07-24 |
| Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (NCT04729387) | Novartis Pharmaceuticals | 2021-07-22 |
| Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal (NCT04511988) | Institut de Cancérologie de Lorraine | 2021-07-17 |
| Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer (NCT05371301) | Fudan University | 2021-07-16 |
| Study of DP303c Injection in Patients With Advanced Ovarian Cancer (NCT04828616) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-01 |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors (NCT04875806) | NextCure, Inc. | 2021-06-30 |
| Spectroscopy in Ovarian Cancer (NCT04817449) | University of Exeter | 2021-06-28 |
| Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living (NCT04458168) | University of Michigan Rogel Cancer Center | 2021-06-28 |
| A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer (NCT04999605) | Akeso | 2021-06-24 |
| Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer (NCT04830709) | AstraZeneca | 2021-06-15 |
| Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer (NCT04911114) | University of British Columbia | 2021-06-15 |
| A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer (NCT04908787) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-06-11 |
| Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (NCT04739527) | University Medical Center Groningen | 2021-06-10 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| PROADAPT-ovary/EWOC-2 (NCT04284969) | Hospices Civils de Lyon | 2021-06-03 |
| VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES (NCT05840029) | Alexandria University | 2021-06-01 |
| (GI-RADS) in Preoperative Evaluation of Adnexal Masses (NCT06403072) | Beni-Suef University | 2021-06-01 |
| D9319C00001- 1L OC Mono Global RCT (NCT04884360) | AstraZeneca | 2021-05-31 |
| Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT04606914) | University of Alabama at Birmingham | 2021-05-27 |
| Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling (NCT05132868) | Stanford University | 2021-05-25 |
| Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study) (NCT04945187) | Rigshospitalet, Denmark | 2021-05-17 |
| Improved Diagnosis of Ovarian Cancer (NCT05842629) | University of Aarhus | 2021-05-15 |
| Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia (NCT04803305) | Pfizer | 2021-05-11 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| A Study of Intra-operative Imaging in Women With Ovarian Cancer (NCT04878094) | Memorial Sloan Kettering Cancer Center | 2021-05-03 |
| Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (NCT04451369) | Institut Paoli-Calmettes | 2021-05-01 |
| Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. (NCT05610501) | Universitaire Ziekenhuizen KU Leuven | 2021-05-01 |
| Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (NCT04375956) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-04-26 |
| PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (NCT05697198) | Labcorp Corporation of America Holdings, Inc | 2021-04-19 |
| Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test (NCT04812938) | Azienda Ospedaliera San Giovanni Battista | 2021-04-12 |
| Thiol-disulfide Homeostasis in Patients With Ovarian Cancer (NCT05011539) | Tepecik Training and Research Hospital | 2021-04-09 |
| CADx - Radiomics to Distinguish the Origin of Ovarian Tumors (NCT05174377) | Gynaecologisch Oncologisch Centrum Zuid | 2021-04-05 |
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer (NCT04630769) | Masonic Cancer Center, University of Minnesota | 2021-04-02 |
| PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer (NCT04815408) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-04-01 |
| Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (NCT04614051) | Pharmicell Co., Ltd. | 2021-03-30 |
| BrUOG 390: Neoadjuvant Treatment With Talazoparib (NCT04598321) | Brown University | 2021-03-29 |
| Phase 1 Dose Escalation of ArtemiCoffee (NCT04805333) | Frederick R. Ueland, M.D. | 2021-03-26 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (NCT04676334) | pharmaand GmbH | 2021-03-22 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors (NCT04731467) | Famewave Ltd. | 2021-03-19 |
| Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact (NCT04731441) | Milton S. Hershey Medical Center | 2021-03-18 |
| Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer (NCT04608409) | Frederick R. Ueland, M.D. | 2021-03-17 |
| Role of the ATP7A Transporter in Ovarian Cancer (NCT05490407) | University Medical Centre Ljubljana | 2021-03-17 |
| Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients (NCT04560452) | AstraZeneca | 2021-03-15 |
| Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet (NCT04898842) | Royal Surrey County Hospital NHS Foundation Trust | 2021-03-02 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| 'OLAP' (OLAparib Regulatory Post-marketing Surveillance) (NCT04553926) | AstraZeneca | 2021-02-01 |
| Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (NCT04038619) | M.D. Anderson Cancer Center | 2021-02-01 |
| Lymphadenectomy in Early Ovarian Cancer (NCT04710797) | Sun Yat-sen University | 2021-01-31 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer (NCT05931445) | Comprehensive Support Project for Oncology Research | 2021-01-26 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (NCT04752826) | BioInvent International AB | 2021-01-25 |
| Prehabilitation in Gynaecological Cancer Patients (NCT04789694) | Charles University, Czech Republic | 2021-01-25 |
| Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. (NCT04699006) | First Affiliated Hospital Xi'an Jiaotong University | 2021-01-21 |
| Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (NCT04507841) | Tongji Hospital | 2021-01-08 |
| Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer (NCT05184140) | Hospital Clinic of Barcelona | 2021-01-01 |
| Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5) (NCT04714931) | Acibadem University | 2021-01-01 |
| A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer (NCT03989336) | Chinese PLA General Hospital | 2020-12-23 |
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (NCT04625270) | Verastem, Inc. | 2020-12-21 |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors (NCT04672460) | Pfizer | 2020-12-21 |
| The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer (NCT04582552) | Xiaoxiang Chen | 2020-12-15 |
| EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (NCT04669002) | Ellipses Pharma | 2020-12-14 |
| Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. (NCT04661696) | Chinese Academy of Medical Sciences | 2020-12-09 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (NCT04590326) | Regeneron Pharmaceuticals | 2020-12-08 |
| Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer (NCT04417192) | National Cancer Center Hospital East | 2020-12-01 |
| Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers (NCT04330716) | Dana-Farber Cancer Institute | 2020-12-01 |
| Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NCT04679064) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-12-01 |
| NeoVax With Nivolumab in Patients With Ovarian Cancer (NCT04024878) | Dana-Farber Cancer Institute | 2020-11-20 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (NCT04644068) | AstraZeneca | 2020-11-12 |
| Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) (NCT04492007) | UNC Lineberger Comprehensive Cancer Center | 2020-11-02 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (NCT04566952) | Xiaoxiang Chen | 2020-10-28 |
| Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors (NCT04640480) | SN BioScience | 2020-10-21 |
| Tempus Priority Study: A Pan-tumor Observational Study (NCT05179824) | Tempus AI | 2020-10-19 |
| Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab (NCT04770376) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2020-10-12 |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (NCT04826198) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-10-05 |
| Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer (NCT04590625) | Zhongshan Hospital Xiamen University | 2020-10-01 |
| Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer (NCT04747717) | N.N. Petrov National Medical Research Center of Oncology | 2020-10-01 |
| Living WELL: A Web-Based Program for Ovarian Cancer Survivors (NCT04533763) | Susan Lutgendorf | 2020-09-30 |